-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$20.007.58% Upside
Entrada Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright in the past 90 days.